USA - NYSE:RBOT - US92561V2088 - Common Stock
ChartMill assigns a Buy % Consensus number of 78% to RBOT. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-08-13 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-03-18 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2024-11-13 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2024-08-13 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2024-07-15 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2024-03-05 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2023-12-04 | Morgan Stanley | Initiate | Equal-Weight |
| 2023-11-14 | BTIG | Downgrade | Buy -> Neutral |
| 2023-11-14 | Canaccord Genuity | Downgrade | Buy -> Hold |
| 2023-05-31 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2022-07-18 | BTIG | Maintains | Buy |
| 2022-05-10 | Piper Sandler | Maintains | Neutral |
| 2022-03-04 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2022-01-07 | Credit Suisse | Initiate | Outperform |
| 2021-12-07 | Cowen & Co. | Initiate | Outperform |
| 2021-11-05 | Canaccord Genuity | Initiate | Buy |
| 2021-10-18 | BTIG | Initiate | Buy |
| 2021-10-07 | Piper Sandler | Initiate | Overweight |
9 analysts have analysed RBOT and the average price target is 10.2 USD. This implies a price increase of 91.37% is expected in the next year compared to the current price of 5.33.
The consensus rating for VICARIOUS SURGICAL INC-A (RBOT) is 77.7778 / 100 . This indicates that analysts generally have a positive outlook on the stock.